Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Oct 22, 2026
TickeronGET DAILY SIGNALS
Thermo Fisher Scientific (TMO) Posts +9% Revenue Growth in Q3 2026 Earnings Beat

Thermo Fisher Scientific (TMO) Posts +9% Revenue Growth in Q3 2026 Earnings Beat

Key Takeaways

  • Third quarter 2026 adjusted EPS (earnings per share) reached $6.68, above the $6.40 consensus estimate.
  • Revenue rose to $12.14 billion, up 9% year over year (6% organic growth), topping the roughly $11.95 billion consensus.
  • Adjusted operating income climbed 15% to $2.97 billion, and adjusted operating margin expanded to 24.5% from 23.3% a year earlier.
  • Laboratory Products and Biopharma Services led the way with 15% growth, while Specialty Diagnostics revenue declined 6.5%.
  • Management raised full-year 2026 guidance for both revenue and adjusted EPS, citing broad end-market strength and a one-time tariff refund benefit.

Earnings Context and Why It Matters

Thermo Fisher Scientific (TMO), the world's largest life sciences tools and services provider, serves pharmaceutical, biotech, diagnostics, and research customers worldwide. Because its results span laboratory consumables, analytical instruments, clinical diagnostics, and contract pharma services, its quarterly report is closely watched as a read on global health-care and biopharma spending. The company has now beaten earnings estimates for four consecutive quarters, and investors use this report to gauge whether demand momentum from earlier in 2026 is continuing. The third quarter also tested how well recent acquisitions, including Clario, are integrating and whether margin expansion is sustainable beyond one-time items. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Reported Results

Thermo Fisher Scientific (TMO) delivered third quarter 2026 adjusted EPS of $6.68, exceeding the consensus estimate of $6.40. Revenue came in at $12.14 billion, ahead of the roughly $11.95 billion expected and up 9% year over year, including 6% organic growth. Adjusted operating income rose 15% to $2.97 billion, and the adjusted operating margin expanded 120 basis points to 24.5%, above the 24% analysts had modeled.

Results were mixed by segment. Laboratory Products and Biopharma Services generated $6.86 billion in revenue, up 15% and above forecasts. Analytical Instruments revenue rose 5.8% to $2.00 billion, while Life Sciences Solutions grew 5.1% to $2.72 billion, slightly below expectations. Specialty Diagnostics declined 6.5% to $1.10 billion, also below consensus.

Management also raised full-year 2026 guidance. Revenue is now expected in a range of $47.7 billion to $48.2 billion, representing 7% to 8% reported growth, while adjusted EPS guidance was lifted to $25.13 to $25.43, implying 10% to 11% growth over 2025. Notably, about $0.15 of the quarterly EPS beat stemmed from one-time tariff refunds recovered during the period, which management said was not included in prior guidance.

Market Reaction and Investor Sentiment

Heading into the report, life sciences tools and services stocks had traded relatively flat over the prior month, with investors awaiting confirmation that demand strength seen earlier in 2026 was persisting. The third quarter beat on both revenue and EPS, coupled with a second consecutive full-year guidance raise, was broadly viewed as a sign that end-market conditions remain constructive, particularly in bioproduction and pharma services. Investors also took note of the meaningful margin expansion, though some analysts flagged that the tariff refunds inflated the quarterly figure on a one-time basis. The softer results in Specialty Diagnostics tempered enthusiasm, reminding the market that not all segments are growing at the same pace.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on whether Thermo Fisher Scientific (TMO) can sustain organic growth and margin gains without the benefit of one-time items. Management pointed to continued strength in customer activity and improving end markets, but the roughly $0.15 per share of tariff-related benefit in the third quarter will not repeat, so fourth quarter comparisons will be watched closely.

Acquisition integration remains a key theme. The Clario acquisition, which strengthens Thermo Fisher's clinical development offering, is performing well, and management expects meaningful revenue synergies over time. The filtration and separation business, which recently marked its one-year anniversary, continues to bolster bioproduction capabilities. The company also completed the divestiture of its microbiology business during the quarter, a reminder that portfolio shaping remains part of its capital deployment strategy.

Other factors to monitor include foreign exchange effects, which provided a modest tailwind in the quarter, and the pace of margin expansion driven by the company's productivity programs and its growing use of AI. Demand signals from pharmaceutical and biotech customers, along with trends in diagnostic testing volumes, will also shape whether the raised full-year guidance proves conservative. Investors should watch for further commentary on capital deployment, including potential M&A and share repurchases.

Using Tickeron’s AI Screener in My Analysis

I’ve found Tickeron’s AI Screener to be a practical addition to my routine when reviewing earnings like these. The tool lets me quickly filter life sciences names by fundamentals, growth trends, and technical signals, helping confirm how Thermo Fisher Scientific (TMO) stacks up against peers without spending hours on manual work. It’s become one of the first places I turn for context on sector momentum.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TMO

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


TMO in -3.35% downward trend, declining for three consecutive days on November 20, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TMO declined for three days, in 198 of 320 cases, the price declined further within the following month. The odds of a continued downward trend are 62%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 66 cases where TMO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TMO as a result. In 46 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.

The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 23 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 55%.

TMO moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.

TMO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a +6.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 192 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.

The Aroon Indicator entered an Uptrend today. In 155 of 256 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 13 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.876) is normal, around the industry mean (67.298). P/E Ratio (37.333) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).

The Tickeron Profit vs. Risk Rating rating for this company is 78 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 20.94B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -10%. For the same Industry, the average monthly price growth was -17%, and the average quarterly price growth was 16%. VCYT experienced the highest price growth at 3%, while ADVB experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 15%. For the same stocks of the Industry, the average monthly volume growth was -35% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 50
SMR Rating: 78
Profit Risk Rating: 88
Seasonality Score: 24 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of analytical and environment monitoring instruments

Industry MedicalSpecialties

Industry
Medical Specialties
Address
168 Third Avenue
Phone
+1 781 622-1000
Employees
125000
Web
https://www.thermofisher.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.
Thermo Fisher Scientific (TMO) Posts +9% Revenue Growth in Q3 2026 Earnings Beat